Great Report!! Thanks for posting Oxxa."Imugene Limited (ASX:...

Great Report!! Thanks for posting Oxxa.

"Imugene Limited (ASX: IMU)IMU was the second best performing stock in the index in November, with the share price increasing 114.3%.

During the month the company announced it had received IND approval from the FDA to initiate a Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx, in the US.

The clinical trial will seek to determine the safety and optimal dose of PD1-Vaxx as a monotherapy in non-small cell lung cancer patients.

During the month, the company also announced the interim results from the Phase II trial of HER-Vaxx in advanced gastric cancer.

The interim analysis showed a statistically significant hazard ratio of 0.418 and a reduced risk of death of 58.2% for those patients treated with HER-Vaxx plus chemotherapy as compared to chemotherapy alone. The median overall survival for patients receiving HER-Vaxx plus chemotherapy was 14.2 months, compared to 8.8 months in patients treated solely with chemotherapy.

The trial indicates that B-cell activating immunotherapy vaccines can induce active antibody responses. There was no added toxicity when HER-Vaxx was combined with the chemotherapy treatment.

The study was designed to measure the efficacy, safety and immune response in 68 patients with metastatic gastric cancer over expressing the HER-2 protein.

Given the significance of the results, the IDMC provided guidance that it is appropriate to reduce the overall number of patients required to complete the study."